ABSTRACT
trough plasma GCV levels does not reliably predict response to therapy. Rather, 28 immunological monitoring (pp65 and IE-1-specific IFN-γ-producing CD8 + T cells) 29 appeared to perform better for this purpose. DNA clearance (2), despite the fact that V-GCV leads to higher exposure than GCV (3).
46
Since intracellular GCV triphosphate is the active form of this compound, plasma GCV 47 concentration is simply a surrogate of drug antiviral activity (1,2 of these T-cell populations on CMV DNAemia clearance (9,10).
60
A total of 13 episodes of CMV DNAemia developing in 13 patients were included in 61 the current study. None of these patients had CMV end-organ disease. Clinical and 62 demographic characteristics of these patients are shown in Universitario. All patients gave written informed consent to participate in the study.
65
Preemptive therapy with oral V-GCV (900 mg/12 h), or i. DNAemia) reaching ≥1 cell/μl were considered significant (9,10).
86
Nine out of the 13 episodes of CMV DNAemia included in the current study were 87 first (initial) episodes, occurring at a median of 28 days after Allo-SCT (range, 0-51 88 days). The remaining 4 episodes were recurrences that developed at a median of 321 89 days after Allo-SCT (range, 144-766 days) (patients 3,9,10 and 13 in Table 2 ). Ten Range, 2-10/patient). CMV-specific CD8 + T-cell levels were determined in 79 94 specimens (median, 5/patient; Range, 2-13/patient). The data are shown in Table 2 from patients 1, 2, and 5 was used for sequence analysis of the UL54 and UL97 genes.
103
These specimens had been obtained at least 4 weeks following antiviral inception, and 104 displayed CMV DNA loads above 1,000 copies/ml, which is approximately the limit of 105 detection of the PCR-sequencing method employed in the current study (9). A mutation 106 known to confer resistance to GCV was only found in patient 5 (M460V in the UL97 
123
There is scant information on whether measurement of plasma GCV levels is of any 124 clinical utility in predicting the response to preemptive therapy in Allo-SCT recipients.
125
In fact, the therapeutic range of plasma GCV concentration has not been formally DNAemia clearance (in whole blood) despite adequate plasma levels during V-GCV 148 treatment for CMV disease in D+/R-SOT recipients.
149
For the current study, leftover plasma specimens which had been submitted to our 150 laboratory for routine CMV DNA load monitoring (performed once a week) were used. 
